Abstract-The binding of 3H-clonidine to bovine brain coated vesicles was studied. The binding was reversible and saturable. Saturation studies revealed a one-site interaction: Kd was 8.7 nM and Bma ,X was 24.5 fmol/mg protein. Noradrenaline, yohimbine and phenoxybenzamine displaced 3H-clonidine binding from the binding sites at concentrations of 10-7-10-4 M. The results indicate that the coated vesicles from the bovine cerebral cortex contain 3H-clonidine binding sites comparable to the low affinity sites of a2-adrenergic receptors in bovine brain membranes.
Coated vesicles with a characteristic outer coat structure are contained in virtually all eukaryotic cells. The vesicles have been implicated in internalization of polypeptide hormones such as low density lipoprotein via receptor-mediated endocytosis (1) . The coated vesicles are also suggested to be involved in the transport of membrane glyco proteins and the nicotinic acetylcholine receptors from the Golgi apparatus to the plasma membrane (2, 3) . 9-Adrenergic receptors have been reported to be present in coated vesicles and supposed to be inter nalized by the vesicles, resulting in desensi tization of this receptor on the plasma mem brane (4) . In addition, muscarinic acetyl choline (5) and opioid receptors (6) were shown to be present in coated vesicles. a2 Adrenergic receptors (a2-receptors) are in volved in the control of a number of important physiological processes and suggested to relate to an etiology of depression (7, 8) . In this study, we examined whether or not a2-receptors would associate with coated vesicles, using 3H-clonidine as a radiolabeled ligand.
Coated vesicles were isolated from fresh bovine brain with a previously described method (9). Briefly, the cerebral cortex was homogenized in 50 mM 2-(N-morpholino) ethanesulfonic acid buffer (pH 6.0) contain ing 1 mM EGTA, 0.5 mM MgCl2 and 0.02% NaN3 (MES buffer) and then centrifuged at 20,000xg for 30 min, followed by a sedimen tation at 55,000xg for 60 min. The resulting pellet was suspended in 10% sucrose in the MES buffer and centrifuged at 100,000 x g for 60 min. The pellet suspended in the same buffer was layered on the top of a 30-50% continuous sucrose density gradient and centrifuged at 55,000 x g for 15 hr. The band at 38-45% sucrose concentrations, enriched in coated vesicles; was collected as the purified coated vesicle preparation. The con tents and purity of the coated vesicle prep aration were examined by electron micro scopy as previously described (10). The vesicles, either spheroid or ellipsoid in shape, had sizes ranging from 70-80 nm in diameter. Membrane fragments, 150-250 nm in size, were occasionally found in the preparation (9). The coated vesicles accounted for 85 95% of the total population of all membranous structures in the present vesicle fraction.
Binding of 3H-clonidine (46.3 Ci/mmol, New England Nuclear) to coated vesicles was determined by a modification of the method of U'Prichard and Snyder (11). Coated vesicles (200-300 ,cg protein) were incubated with 4 nM 3H-clonidine in 50 mM Tris-HCI buffer (pH 7.4) in a standard assay volume of 0.5 ml at 30°C for 1 .5 hr. The reaction was terminated by rapid filtration through Whatman GF/B filters, which were im mediately washed with 3x3 ml aliquots of ice-cold Tris-HCI buffer. The radioactivity on the filters was counted on a liquid scintillation spectrometer.
Specific binding was deter mined as the difference between the total binding and that in the presence of 10 ,aM clonidine. For the Scatchard plot, the coated vesicles were incubated with various concen trations of 3H-clonidine The binding was rapidly reversed by the addition of 10 uM non-labeled clonidine, and the half time for the dissociation was 5 min. In the saturation experiments, non-specific binding linearly increased with increasing 3H clonidine concentrations in the incubation medium, while levels of specific binding plateaued at about 25 nM (Fla. 1A). Half maximal specific binding was observed at about 8 nM. A Scatchard plot of the saturation isotherm indicated a one-site interaction (Fig.  1 B) . From five such experiments using dif ferent coated vesicle preparations, the Kd was 8.7+1.0 nM, and the mean Bmax was 24.5+ 2.4 fmo!/mg protein. Two binding sites for 3H-clonidine , low and high affinity, were not observed in the coated vesicle preparation. This was different from the findings obtained by Randall et al. with a preparation of crude synaptosomal membranes from bovine cere bra! cortex (bovine brain membranes) (12). These preceding investigators have shown that 3H-clonidine, 0.01--50 nM concen trations, labeled both high (K,=0.38 nM) and low affinity binding sites (K,=5.9 nM) for a2-receptors using binding conditions similar to those of our present study (12). The Kd value, 8.7 nM, for 3H-clonidine binding to the coated vesicles was comparable to that, 5.9 nM, of the low affinity binding site obtained with the bovine brain membrane a2 receptors. In the coated vesicles, 3H-clonidine may label a low affinity binding site for a2 receptors. The Bmax value, 24.5 fmol/mg pro tein, was 8-fold lower than that, 210 fmol/mg protein, reported in the bovine brain mem branes (12). A low value of Bmax has also been observed in the (3-receptors in bovine brain coated vesicles; it was one-sixth of that of synaptic plasma membranes (4) . Figure 2 shows that 3H-clonidine binding to the coated vesicles was displaced by several a-adrenergic agonists and antagonists in a concentration ranging from 10-7 to 10-4 M. The rank order of the potency for the displacing agents was clonidine>noradrena line>phenoxybenzamine>yohimbine. Prazo sin, a highly specific a1-antagonist, was 1000 times less potent than clonidine. Dis placement studies suggested that 3H clonidine labeled a2-receptors in the coated vesicles. However, high concentration (10-7 10-4 M) of the agonists and antagonists was required to displace the 3H-clonidine binding from coated vesicles, compared to that for the a2-receptors in the bovine brain mem branes (11). The presence of guanosine 5' triphosphate (GTP, 10-4 M) did not shift the displacing curve of clonidine to the right (data not shown). This suggests that a high-affinity, nucleotide-sensitive, complex with the agonist was not formed in the coated vesicles, which is different from what was observed in bovine brain membranes (12). This finding appeared to be consistent with the result that 3H-clonidine labeled only the low affinity binding site in the coated vesicles as shown in Fig. 1 B. A similar finding that a GTP analogue did not change the effect of an agonist on ligand binding has been observed in the (9-receptors present in the brain coated vesicle fraction (4) .
The present results strongly suggest that a part of the intracellular a2-receptors is associated with coated vesicles involved in the endocytotic or exocytotic vesicular traffic having an origin in plasma membranes or the Golgi apparatus (1-3) . However, the 3H clonidine binding sites associated with coated vesicles differed in some points from those shown in the bovine brain membranes (12) : for example, no high affinity binding sites for 3H-clonidine was observed , and GTP did not affect the displacing curve of clonidine to 3H clonidine binding. It has also been reported that clonidine binds to imidazole binding sites as well as a2-receptors in the brain and that the binding sites are estimated to be 13% of the total clonidine binding in the frontal cortex (13). The exact relationships between the a2 receptors and 3H-clonidine binding sites in coated vesicles await further clarification. The coated vesicles used in this study ranged from 70 to 80 nm in diameter, which were com parable to that for this type of vesicles dis tributing in the area of the Golgi apparatus (14). At present, it is unclear, as discussed by the preceding investigators (4), whether the coated vesicles possess a normalized inherent size, suggesting the difference of their mother structures.
Further studies, morphological as well as biochemical, are needed to clarify whether the coated vesicles with a diameter size of 70-80 nm are transporting a2 receptors along the centripetal or centrifugal traffic.
